This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Von Hippel-Lindau genetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Genetic linkage studies in families with the von Hippel-Lindau syndrome indicate that the gene involved in the von Hippel-Lindau suppressor protein (pVHL) is on chromosome 3p25:

  • pVHL - this has been shown to bind directly to the alpha subunits of the heterodimeric transcription factor HIF (hypoxia inducible factor)
  • pVHL directs the polyubiquitination and, hence, destruction of HIF in the presence of oxygen
  • loss of pVHL function leads to deregulation of HIF target genes (these play critical roles in angiogenesis)

Note that:

  • 85% of all tumours of the renal parenchyma have mutations of the VHL gene
  • 67% of all renal adenocarinomas have mutations of the VHL gene

Reference:

  1. Ivan M, Kaelin WG (2001). The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev.11(1):27-34.
  2. Karp, J.E. & Broder, S. (1995). Molecular foundations of cancer: new targets for intervention. Nature Med. 1(4), 309-320
  3. Iliopoulos, O. et al. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nature Med. 1(8), 822-826

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.